Regular review: Managing testicular cancer

British Medical Journal

Volumn 322, Issue 7302, 2001, Pages 1583-1588

  Dearnaley, D P ^a   Huddart, R A ^a   Horwich, A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIEMETIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; STEROID;

CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG INDUCED DISEASE; FOLLOW UP; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; MALE; ORCHIECTOMY; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEMINOMA; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; TESTIS CANCER; TREATMENT PLANNING;

EID: 0035974446     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.322.7302.1583     Document Type: Review

References (35)

1. Guidelines on the management of adult testicular cancer
2. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract?
3. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours
4. The aetiology of testicular cancer: Association with congenital abnormalities, age at puberty, infertility and excercise
5. Testicular nonseminoma and seminoma in relation to perinatal characteristics
6. Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adults
7. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer. Defining a high risk group
8. Public awareness of testicular cancer and the value of self examination
9. Testicular cancer
10. Medical Research Council prospective study of surveillance for stage I testicular teratoma
11. Adjuvant chemotherapy in high risk stage 1 non-seminomatous germ cell tumours of the testis
12. Management of stage I seminoma: Radiotherapy
13. Prognostic factors for relapse in stage I seminoma managed by surveillance
14. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers
15. Cis-diammine-dichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer
16. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)
17. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
18. Intensive reduction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/ European Organization for Research and Treatment of Cancer study
19. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
20. Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: A randomised study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
21. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council
22. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy
23. Intensive induction treatment for poor risk patients
24. Combination carboplatin and radiotherapy in the management of stage IIA and stage IIb testicular seminoma: Comparison with radiotherapy treatment alone
25. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastanic seminoma
26. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables
27. Salvage therapy of germ cell tumours
28. The health of long term survivors of testicular cancer
29. Avascular necrosis in patients treated with BEP chemotherapy for testicular tumours
30. Fertility after chemotherapy for testicular germ cell cancers
31. Risk of second malignant neoplasms among long-term survivors of testicutar cancer
32. Cardiovascular morbidity in long-term survivors of metastatic testicutar cancer
33. Evaluation of adjuvant psychological therapy in patients with testicular cancer: Randomised controlled trial
34. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse